A combination of commonly used FOLFOX therapy and ERK inhibition by U0126 significantly improved the response of CRC cells in our model, and represents a promising new therapeutic option for the subgroup of MMR-deficient CRCs presented here, which may be able to escape ICI therapy. The gene discussed is MRC1; the disease is colorectal carcinoma.